

Resource Summary Report

Generated by PRECISE-TBI on Sep 7, 2026

Immune Tolerance Network TrialShare

RRID:SCR_013699

Type: Tool

Proper Citation

Immune Tolerance Network TrialShare (RRID:SCR_013699)

Resource Information

URL: <https://www.itntrialshare.org/>

Proper Citation: Immune Tolerance Network TrialShare (RRID:SCR_013699)

Description: Immune tolerance data management and visualization portal for studies sponsored by Immune Tolerance Network (ITN) and collaborating investigators. Data from published studies are accessible to any user; data from current in-progress studies are accessible to study investigators and collaborators. Includes links to published Figures, tools for visualization and analysis of data, and ability to query study data by subject, group, or any other study parameter.

Abbreviations: ITN TrialShare, TrialShare

Synonyms: , ITN, TrialShare, Trial Share, Immune Tolerance Network

Resource Type: clinical trial, data or information resource, data repository, service resource, storage service resource

Keywords: clinical trial, clinical data, biological specimens,

Related Condition: Type 1 diabetes, Diabetes, Allergy, Asthma, Autoimmune disease, Transplantation, Immunological disorder

Funding: NIAID

Availability: Restricted

Resource Name: Immune Tolerance Network TrialShare

Resource ID: SCR_013699

Alternate URLs:

<https://www.itntrialshare.org/login/home/login.view?returnUrl=%2Fproject%2Fhome%2Fstart.view%3>

License URLs: <https://www.itntrialshare.org/itn/Terms Of Use.html>

Record Creation Time: 20220129T080317+0000

Record Last Update: 20260905T132739+0000

Ratings and Alerts

No rating or validation information has been found for Immune Tolerance Network TrialShare.

No alerts have been found for Immune Tolerance Network TrialShare.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Evans-Molina C, et al. (2026) Beta cell glucose sensitivity identifies clinical response to disease-modifying therapies initiated at stage 3 type 1 diabetes onset. *Diabetologia*, 69(6), 1482.

SoRelle ED, et al. (2025) Early multiple sclerosis activity associated with TBX21+CD21loCXCR3+ B cell expansion resembling EBV-induced phenotypes. *JCI insight*, 10(12).

Lledó-Delgado A, et al. (2025) Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes. *Nature communications*, 16(1), 5033.

Higdon LE, et al. (2025) Early expansion of TIGIT+PD1+ effector memory CD4 T cells via agonistic effect of alefacept in new-onset type 1 diabetes. *Journal of immunology* (Baltimore, Md. : 1950), 214(1), 12.

Higdon LE, et al. (2024) Impact on in-depth immunophenotyping of delay to peripheral blood processing. *Clinical and experimental immunology*, 217(2), 119.

Baloh CH, et al. (2024) Peanut-specific IgG subclasses as biomarkers of peanut allergy in LEAP study participants. *The World Allergy Organization journal*, 17(8), 100940.

Xiao Q, et al. (2023) Immunosuppression causes dynamic changes in expression QTLs in psoriatic skin. *Nature communications*, 14(1), 6268.

Ylescupidez A, et al. (2023) A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes. *Nature communications*, 14(1), 7214.

Kanchan K, et al. (2022) HLA alleles and sustained peanut consumption promote IgG4 responses in subjects protected from peanut allergy. *The Journal of clinical investigation*, 132(1).

Mexhitaj I, et al. (2022) Stabilization of leukocytes from cerebrospinal fluid for central immunophenotypic evaluation in multicenter clinical trials. *Journal of immunological methods*, 510, 113344.

Atisha-Fregoso Y, et al. (2021) Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. *Arthritis & rheumatology* (Hoboken, N.J.), 73(1), 121.

Greenbaum CJ, et al. (2021) IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes. *JCI insight*, 6(21).

Diggins KE, et al. (2021) Exhausted-like CD8⁺ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects. *JCI insight*, 6(3).

Huffaker MF, et al. (2021) Approaches to Establishing Tolerance in Immune Mediated Diseases. *Frontiers in immunology*, 12, 744804.

Perkin MR, et al. (2021) Association of frequent moisturizer use in early infancy with the development of food allergy. *The Journal of allergy and clinical immunology*, 147(3), 967.

Shamji MH, et al. (2021) Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy. *The Journal of allergy and clinical immunology*, 148(4), 1061.

Owczarczyk K, et al. (2020) Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis. *JCI insight*, 5(18).

Larson D, et al. (2020) Nasal allergen challenge and environmental exposure chamber challenge: A randomized trial comparing clinical and biological responses to cat allergen. *The Journal of allergy and clinical immunology*, 145(6), 1585.

Santos AF, et al. (2020) Biomarkers of severity and threshold of allergic reactions during oral peanut challenges. *The Journal of allergy and clinical immunology*, 146(2), 344.

Perkin MR, et al. (2019) Factors influencing adherence in a trial of early introduction of allergenic food. *The Journal of allergy and clinical immunology*, 144(6), 1595.